ResMed’s AirFit F20 and N20 Now Available, The Only CPAP Masks with InfinitySeal™ for Maximum Fit and Comfort

The AirFit 20 series masks tested on more than 600 patients

SAN DIEGO – November 22, 2016 – ResMed today announced that its new AirFit™ F20 full face mask and N20 nasal mask are now available in the United States.

The AirFit 20 series introduces a new InfinitySealTM silicone cushion that adapts to the unique facial contours of each patient and is designed to provide a universal fit for all patients, regardless of face shape or size. Plus, both masks feature magnetic clips for easy fit and removal.

Tested to perform at high therapy pressures, the AirFit F20 full face mask provided an effective seal for more than 97 percent of patients, while the AirFit N20 nasal mask sealed on more than 99 percent.

Rave reviews

Patients were impressed with the masks’ easy and effective seal. Anonymous quotes from ResMed’s clinical studies include:

  • “I really like the AirFit N20. No areas of discomfort. It’s a home run.”
  • “The AirFit N20 is quite comfortable, less weight on the face, feels much lighter [compared to leading nasal masks in side-by-side comparison].”
  • “The AirFit F20 felt real good – I was about to go to sleep. I would definitely get this one.”
  • “I could tell immediately the F20 would hold the [seal at the high] pressure. Also the headgear didn’t need adjustment.”
  • “I love the magnets.”

About ResMed

ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 2 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.

ResMed.com | Facebook | Twitter | LinkedIn

# # #